ASCO 2024: Clinical Implications of New CML Data

Jorge E. Cortes, MD

June 25, 2024

Jorge E. Cortes, MD, reflects on key insights from ASCO 2024, starting with the ASC4FIRST study, which compared asciminib with other frontline treatments for chronic myeloid leukemia (CML). In noting the new data on asciminib, Dr Cortes comments that clinicians will potentially have five different TKIs to consider, enhancing treatment flexibility.

Dr Cortes also emphasizes the importance of deeper molecular responses and the potential for treatment discontinuation, suggesting that asciminib may be particularly beneficial for patients aiming to stop therapy. He also notes asciminib's reduced toxicity compared with other TKIs, making it a safer option for frail or comorbid patients, and that further follow-up is needed to confirm these early results.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ASCO 2024: Clinical Implications of New CML Data - Medscape - Jun 25, 2024.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

ASCO 2024: Clinical Implications of New CML Data

Tables

Authors and Disclosures

Authors and Disclosures

Expert

Jorge E. Cortes, MD

Comments

Email This

Feedback